SCHEMBL10312233

SCHEMBL10312233

CN1CCCN(c2nc(/C=C/c3cccc(C(F)(F)F)c3)nc(Nc3cc(C4CC4)[nH]n3)n2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 5/20 0.56
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
IGF1R P08069 3/20 0.43
MAPT P10636 1/20 0.41
IDH2 P48735 2/20 0.41
AURKA O14965 3/20 0.40
NTRK1 P04629 3/20 0.40
PLK4 O00444 2/20 0.40
ABL1 P00519 2/20 0.40
LCK P06239 2/20 0.40
CSF1R P07333 2/20 0.40
RET P07949 2/20 0.40
KIT P10721 2/20 0.40
FGFR1 P11362 2/20 0.40
SRC P12931 2/20 0.40
PDGFRA P16234 2/20 0.40
TYK2 P29597 2/20 0.40
KDR P35968 2/20 0.40
FLT3 P36888 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312076 0.97 HRH4 (0.59) HRH4USP2SMN1; SMN2IGF1RIDH2
SCHEMBL10312180 0.93 HRH4 (0.48) HRH4IGF1RMAPTIDH2CCNA2
SCHEMBL10312209 0.90 HRH4 (0.54) HRH4IGF1RAURKANTRK1PLK4
SCHEMBL16556877 0.89 HRH4 (0.59) HRH4USP2SMN1; SMN2MAPTIDH2
SCHEMBL10312170 0.88 HRH4 (0.54) HRH4IGF1RAURKANTRK1PLK4
SCHEMBL10312080 0.88 IDH2 (0.51) HRH4IGF1RMAPTIDH2PAK4
SCHEMBL10312226 0.88 HRH4 (0.47) HRH4USP2SMN1; SMN2IGF1RMAPT
SCHEMBL10312184 0.88 USP2 (0.46) HRH4USP2SMN1; SMN2IGF1RMAPT
SCHEMBL10312174 0.87 HRH4 (0.46) HRH4USP2SMN1; SMN2IGF1RMAPT
SCHEMBL10312164 0.86 HRH4 (0.57) HRH4IGF1RAURKANTRK1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 HRH4 2393/4885USP2 1096/4885SMN1; SMN2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.